Prion protein (PrP) is a normal endogenous protein of unknown function found in cells of brain and a variety of other mammalian tissues (8, 11, 12, 17, 25, 26, 32) . In the brains of humans and animals afflicted with CreutzfeldtJakob disease, kuru, scrapie, and other transmissible degenerative neuropathies, PrP accumulates in a proteinase Kresistant form (PrP-res) which can aggregate into fibrils (12, 13, 17, 23, 25, 32, 36) and be a component of amyloidlike plaques (19) . {Several names have been used for forms of PrP derived from scrapie-infected tissues [PrP 27-30 (5), PrPsc (25) , scrapie-associated fibril protein (13) , Gp34 (33) , and Sp 33-37 (3)] and uninfected tissues [PrPC (25) and ]. Wishing to avoid terms which assume a relationship of the various forms of this protein to scrapie infectivity or specify a particular size for the protein, we have opted for the operational terms PrP-res and PrP-sen, which label two forms of the protein as they are distinguished experimentally by proteinase K digestion and can encompass the multiple molecular masses of the two forms.} This abnormal form of PrP has been identified as the major protein component of brain fractions containing the transmissible scrapie agent (4, 13, 23) . Because the transmissible agents of scrapie and related diseases are highly resistant to treatments harmful to nucleic acids and because no agent-specific nucleic acids have been identified, it has long been postulated that these agents are devoid of nucleic acid and composed primarily of protein (1, 15, 27, 28) . More recently, it was proposed that PrP-res, or an aggregate thereof, is the transmissible agent of scrapie (4, 13, 24) . However, it is not yet clear whether PrP-res is the transmissible scrapie agent itself, a component of the agent, or a by-product of either the infectious process or the disease.
The chemical basis for the difference between PrP-res and the proteinase K-sensitive PrP (PrP-sen) found in many normal cells and tissues is not known. Scrapie infection does not appear to modify the endogenous PrP gene of brain (2) or the size and quantity of PrP mRNA (8, 11, 26) . Furthermore, expression of the PrP gene cloned from scrapie-infected mouse brain is not sufficient to generate PrP-res or the scrapie agent in mouse tissue culture cells (10) . Thus, the PrP mRNA expressed in scrapie-infected brain does not appear to encode a unique scrapie-specific sequence. Rather, it seems more likely that posttranslational modification of PrP itself leads to the aggregation and accumulation of PrP-res in a proteinase K-resistant form. Several posttranslational modifications of PrP are known to occur (6, 9, 10, 16, 22, 34) , but none has been found to be scrapie specific. It is possible that proteinase K resistance does not require covalent modification but instead requires aggregation, conformational change, or association of PrP-sen with other components of scrapie-infected tissues.
To provide a system in which PrP and the scrapie agent can be studied in the absence of in vivo tissue pathology, we developed scrapie-infected mouse neuroblastoma clones with a high percentage of infected cells (29, 30) . PrP can be labeled metabolically and immunoprecipitated from both uninfected (sc-) and scrapie-infected (sc+) neuroblastoma clones (29) . The PrP detected in this manner in either type of clone is sensitive to proteinase K digestion in detergent lysates and, thus, by definition, is PrP-sen. Biosynthetic studies indicated that the mature PrP-sen of both the sc-and sc+ clones consists of two major glycosylated forms of 30 and 35 to 41 kilodaltons (kDa) which are anchored at the cell surface by covalent linkage to phosphatidylinositol (9) . No scrapie-associated differences in PrP-sen biosynthesis were observed. Recently, however, the detection of PrP-res in scrapie-infected mouse neuroblastoma cells by immunoblotting was reported (7). Here we report the detection of PrP-res in similar sc+ neuroblastoma cells and show, in addition, that PrP-res in intact cells differs from PrP-sen in its sensitivity to proteases and phosphatidylinositol-specific phospholipase C (PIPLC).
MATERIALS AND METHODS
Neuroblastoma cells. The neuroblastoma cell clones 321, 322, and 324 used in these experiments are subclones of the 29-161 clone described in detail before (29, 30 (36) . A portion of the whole anti-PrP peptide rabbit serum (no. 9) obtained was affinity purified, using a protocol provided by Michael Buchmeier (26a) as follows. A 10-mg portion of peptide lb in 10 ml of 0.5 M NaCl-0.1 M Tris hydrochloride, pH 7.5, at 20°C (buffer A) was bound to 0.5 g of thiopropyl-Sepharose (Pharmacia, Uppsala, Sweden) swollen in buffer A by agitating for 1 h at room temperature. The Sepharose beads were pelleted and washed twice with buffer A. The beads were mixed with 10 ml of 0.1 M sodium citrate, pH 4.5, and 5 [LI of 2-mercaptoethanol for 1 h at room temperature, washed extensively with buffer A on a sintered-glass filter, suspended in phosphate-buffered saline (PBS), and packed in a column. Clarified anti-PrP peptide serum (2 ml) was passed through the column, and the column was washed with PBS until the A280 of the effluent was stable. Bound antibodies were eluted with 6 ml of 0.1 M sodium citrate, pH 3.0, immediately neutralized to pH 7 to 8 with 1 M Tris base, dialyzed against PBS, and then concentrated to the original serum volume. A polyclonal rabbit antiserum (R073) raised against hamster PrP 27-30 was provided by S. Prusiner, University of California, San Francisco.
Detection of PrP-res by immunoblotting. We were previously unable to detect PrP-res in our cloned sc+ neuroblastoma cells (29) . However, after modifications of the cell extraction, proteinase K treatment, and protein precipitation procedures, we were able to detect PrP-res in this clone of sc+ neuroblastoma cells. PrP 30 min and chased with medium containing methionine for 150 min as described previously (9) . The intact cells were then incubated with PIPLC, trypsin, or proteinase K as described above, washed twice in minimal essential medium, and lysed in lysing buffer (29) supple-mented with 1 mg of soybean trypsin inhibitor per ml and 1 mM PMSF. PrP was detected in the lysates and in the PIPLC medium by immunoprecipitation, SDS-PAGE, and fluorography as described previously (29) The cells were fixed in PBBS containing 1.5% formaldehyde (freshly diluted from a 37% formaldehyde stock) for 30 min, rinsed twice with PBBS, and incubated in PBBS containing 100 mM glycine-0.1% bovine serum albumin for 30 min. The cells were rinsed twice in PBBS, permeabilized with a 3-min incubation in PBBS containing 0.4% (vol/vol) Triton X-100, and again rinsed twice in PBBS. The cells were then incubated for 30 to 60 min in 200 Rd, per well, of a 1:100 dilution of affinity-purified anti-PrP peptide lb in PBBS supplemented with 2% FBS and 10 mM sodium azide. After rinsing three times with the antibody diluent, the cells were incubated under the same conditions with a 1:200 dilution of fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulin G. After three more rinses in diluent, the cells were mounted in 50% glycerol-2% Formalin and observed under a fluorescence microscope.
Assay of scrapie infectivity. Flasks (75 cm2) of sc+ clone 29-161 cells were treated with PIPLC or trypsin as described above. Thereafter, the cells were counted, frozen, thawed, and sonicated. Cellular debris was removed by centrifuging at 1,000 x g for 5 min. The media from the PIPLC treatments were collected, and detached cells were removed by centrifuging at 1,000 x g for 5 min. The medium samples were then centrifuged at 140,000 x g for 60 (experiment 1) or 180 (experiment 2) min. The supernatants were removed and the pellets were suspended in 1 ml of PBS by sonicating and vortexing. Scrapie infectivity titers in the cleared cell lysates, medium pellets, and medium supernatants were determined by endpoint dilution bioassay in mice as described previously (29 with detergent, treated with proteinase K, and immunoblotted, using anti-PrP peptide lb, anti-PrP peptide lb preabsorbed with synthetic peptide lb, or anti-PrP 27-30. Some 1.5 x 107 cell equivalents were loaded into each lane. Bands containing the specific PrP peptide epitope were those which disappeared when the anti-Prp peptide was preabsorbed. The major band stained by the antisera in both the sc-and sc+ clones which was not removed by preabsorption of the antiserum with peptide lb appeared to be proteinase K since immunoblotting of proteinase K alone produced a similar band (data not shown). The estimated molecular masses (in kilodaltons) of the specific PrP bands in the neuroblastoma cell extracts are indicated on the right.
were estimated by using the method of Spearman and Karber as modified by Irwin and Cheeseman (14) .
RESULTS
Detection of PrP-res. To study the relationship between PrP-res and scrapie infectivity, we sought to determine whether PrP-res could be detected in vitro, i.e., in scrapieinfected tissue culture cells, as it is in scrapie-infected tissues. Detergent extracts of sc-and sc+ mouse neuroblastoma cell clones were treated with proteinase K, and, resistant proteins were visualized by immunoblot, using rabbit antiserum against peptide lb. Proteinase K-resistant bands unique to the sc+ clone were observed (Fig. 1) . Preabsorption of the primary antibody with the synthetic PrP peptide antigen abolished the staining of two major bands with apparent molecular masses of 19 and 23 kDa and a more diffuse group of bands centered around 28 kDa, indicating that these bands contained the PrP peptide epitope. These apparent PrP bands comigrated with the proteinase Ktreated PrP-res bands from scrapie-infected mouse brain (not shown), and the apparent molecular mass values were similar to those reported previously for PrP-res from scrapie mouse brain (18) and sc+ neuroblastoma cells (7) . The same bands were also stained with an antiserum raised against 27-to 30-kDa PrP-res from scrapie-infected hamster brain (Fig.  1) but not with normal rabbit serum (not shown). Thus, based on the immunoreactivity, the apparent molecular masses, and the proteinase K resistance of the 19-, 23-, and 28-kDa bands, we concluded that they were PrP-res.
Resistance of PrP-res in intact sc+ cells to PIPLC and proteases. Having detected scrapie-associated PrP-res in tissue culture cells, we sought ways to discriminate PrP-res from PrP-sen which might suggest differences in posttranslational modification or subcellular localization or both. Since we have shown qualitatively in a previous study that metabolically labeled and immunoprecipitable PrP-sen could be digested on the surface of intact cells by PIPLC and protease treatments (9), we tested whether the same was true for PrP-res. Intact sc+ cells were treated with PIPLC, proteinase K, or trypsin before lysis and were analyzed for PrP-res by immunoblotting (Fig. 2) . The amount of PrP-res detected in the cells was not affected by any of these treatments. Dilutions of cell lysate indicated that even a twofold fold reduction of PrP-res in the cells would have been detected readily by this procedure (Fig. 2) . Additional experiments showed that PrP-res in intact cells was similarly resistant to two other broadly acting proteases, pronase and papain (data not shown). This resistance of PrP-res to PIPLC and the proteases in intact cells indicated that either PrP-res was not on the cell surface or that it existed there in a state that was resistant to these hydrolytic enzymes.
Sensitivity of PrP-sen to phospholipase and proteases. To compare the protease and PIPLC sensitivities of PrP-sen and PrP-res in intact sc+ neuroblastoma cells, it was necessary to quantitate the proportion of PrP-sen that was susceptible to these enzymes. Thus, we expanded on our previous qualitative studies of the release of metabolically labeled PrP by PIPLC and trypsin (9) by adding a proteinase K treatment and by quantitating the proportion digested by each treatment, using densitometry. sc+ cells were pulse-labeled with [35S]methionine and chased for a period which, based on our earlier study (9) , was sufficient to allow translocation of labeled PrP-sen to the cell surface. raphy, and laser densitometry of fluorography films. Figure 3 shows that -90% of both the labeled 30-and 35-to 41-kDa PrP bands were removed from sc+ cells with these enzymes. Thus, most of the immunoprecipitable, [35S]methioninelabeled PrP was chased to the cell surface in a state that was sensitive to proteases and PIPLC.
To confirm these results and to determine whether the metabolically labeled PrP was representative of most of the immunoreactive PrP on the cell surface, we performed membrane immunofluorescence studies. Affinity-purified anti-PrP peptide antibodies readily detected PrP on the surface of live neuroblastoma cells (Fig. 4) . Preabsorption of the primary antibody with peptide lb reduced the fluorescence of the cells to near-background levels, indicating that most of the staining was specific for the PrP peptide epitope. To determine whether the immunoreactive PrP on the cell surface was sensitive to proteinase K, trypsin, and PIPLC, we pretreated the cells with these enzymes prior to immunofluorescent labeling. A representative histogram of proteinase K-pretreated cells is included in Fig. 4 to show that it was nearly superimposed on the background peak. To obtain estimates of the proportions of the immunoreactive PrP removed by proteinase K, trypsin, and PIPLC treatments, specific mean fluorescence intensities of the membrane fluorescence-labeled cell populations were compared ( PIPLC treatment was not affected by increasing the activity of the enzyme and, as noted above, may represent an inherently PIPLC-resistant PrP subfraction or an artifact of the treatment procedure. These immunofluorescence data provided evidence to confirm the immunoprecipitation experiments showing that most of the PrP-sen is sensitive to the proteinase K, trypsin, and PIPLC on the surface of intact cells. This is in contrast to PrP-res, whose detection by immunoblotting was unaffected by these treatments. The observation that similar percentages of the PrP remained on the cell surface after treatments of both sc-and sc+ cells suggested that the residual fluorescence in sc+ cells was not due primarily to PrP-res.
Relative amounts of PrP-res and PrP-sen in sc+ cells. To test whether a portion of the residual cell surface immunofluorescence observed after protease and PIPLC treatments of intact sc+ neuroblastoma cells represented PrP-res, we estimated the relative proportions of PrP-res and PrP-sen in the cells. The inability to detect PrP-sen cleanly in crude cell lysates by immunoblot prevented a direct comparison of PrP-sen and PrP-res in lysates. However, PrP-sen was detected by immunoblot in the medium of PIPLC-treated sc + cells (Fig. 6) . The apparent molecular masses of the observed PrP bands at 30 and 35 to 41 kDa were the same as those of PrP-sen observed by metabolic labeling and immunoprecipitation (9, 29) . Preabsorption of the antibody with peptide lb eliminated the staining of these bands preferentially, indicating that they contained the PrP peptide epitope. Other experiments showed that treatment of the medium with as little as 5 pug of proteinase K per ml for 15 min at ambient temperature eliminated these PrP bands, confirming that they were PrP-sen (data not shown). Immunofluorescent labeling and flow cytometric analysis of samples of the cells used in Fig. 6 indicated that PIPLC and proteinase K treatments of the intact cells reduced the cell surface PrP (Fig. 7) . In both cell types, the fixation and permeabilization procedures eliminated the cell surface signal; however, discrete cytoplasmic structures stained with the affinitypurified anti-PrP peptide antibodies (Fig. 7A to C) . This staining was not observed when the antibody was preabsorbed with the synthetic PrP peptide antigen (Fig. 7D to F) . The stained structures had the morphological appearance of Golgi bodies in that they had a polar perinuclear distribution. Since PrP is a plasma membrane glycoprotein and therefore undergoes carbohydrate processing in the Golgi body during its biosynthesis (9) , the presence of PrP staining in the Golgi body would not be surprising.
No difference was observed in the staining of most of the cells of the sc-and sc+ cultures ( Fig. 7A and B) . However, the staining pattern appeared more dispersed in some cells of the sc+ cultures (Fig. 7C) . The more dispersed appearance was usually associated with cells of quite broad and flattened morphology. Immunoblot analysis of the sc+ cells used in the experiment in Fig. 7 Since the presence of PrP-res correlates with scrapie infectivity in neuroblastoma cells and in other systems, it is important to understand the difference between PrP-sen and PrP-res as well as the possible role of PrP-res in scrapie agent replication or pathology or both. The ability to detect both PrP-sen and PrP-res in sc+ neuroblastoma clones has enabled us to begin studying these topics in vitro. In the present study, we have demonstrated that PrP-sen and PrP-res differ in their sensitivities to PIPLC and proteases in intact cells, the latter being insensitive to these enzymes. There are several possible explanations for these differences. For example, whereas mature metabolically labeled PrP-sen is found on the cell surface (9, 10), PrP-res may be intracellular and thus unavailable to extracellular enzymes.
Alternatively, PrP-res may be on the cell surface, but in a state in which the phospholipase and protease cleavage sites are protected. This could be due to an altered conformation, posttranslational modification, or aggregation of PrP-res. The precise localization of PrP-res in the sc+ neuroblastoma FIG. 7. Cytoplasmic immunofluorescent labeling of PrP in neuroblastoma cells. sc-(clone 324; panels A and D) and sc+ (clone 322; panels B, C, E, and F) neuroblastoma cultures were fixed with formaldehyde, permeabilized with Triton X-100, and stained by using either affinity-purified anti-PrP peptide antibody (panels A to C) or the same antibody preabsorbed with peptide lb (panels D to F) as the primary antibody. Fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulin G was the secondary antibody in all cases. The fluorescence staining was photographed at x 1,280 magnification on a fluorescence microscope.
VOL. 64, 1990 on December 22, 2017 by guest http://jvi.asm.org/ Downloaded from clones has been hampered by the lack of antibodies known to react with this species in its native state. Although the anti-PrP peptide antiserum clearly recognizes PrP-res on immunoblot filters after denaturation in SDS-PAGE, we have no evidence that it binds to PrP-res under the milder conditions used for immunofluorescence or immunoprecipitation. Thus, further localization studies may require the use of other antibodies specific for PrP-res or the development of cell treatments which do not destroy cellular morphology but sufficiently denature PrP-res to make it reactive with our present antibodies.
The reason for the presence of a subpopulation of cells in the sc+ cultures which have a broad and flattened shape and a dispersed cytoplasmic PrP staining pattern is unknown. While it is possible that these cells represent high scrapie producers within the cultures, they may be merely morphological variants which are unrelated to scrapie infection.
It is interesting that, in both sc-and sc+ neuroblastoma clones, about 25% of the fluorescence-labeled PrP-sen on the surface of neuroblastoma cells was resistant to PIPLC digestion. This suggests that a portion of the normal cell surface PrP may lack the glycosyl phosphatidylinositol anchor or may have a modified anchor as has been observed with acetylcholine esterase (31) . Alternatively, aggregation of the cells after EDTA treatment may have protected some of the cell surface PrP from PIPLC digestion because, unlike trypsin and proteinase K, PIPLC may be unable to disaggregate cells on its own.
The finding that scrapie infectivity remained associated with the neuroblastoma cells during treatments which remove mature PrP-sen from the cell is consistent with the idea that two different forms of PrP exist in these cells and that only one of them, PrP-res, appears to correlate with scrapie infectivity. However, this correlation does not prove a structural association between PrP-res and the infectious agent.
